^
    Back
    Association details:
    Biomarker:CD123 positive
    Cancer:Acute Myelogenous Leukemia
    Drug:Campath (alemtuzumab) (CD52 inhibitor) +
    UCART123 (CD123-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    981 Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

    Published date:
    11/03/2022
    Excerpt:
    Adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123v1.2 cell expansion and persistence, which correlated with improved activity and safety, including one pt in the DL2 FCA arm who achieved a durable MRD-negative CR. Overall, these data support the safety and activity of UCART123v1.2 after FCA LD in pts with CD123+ R/R AML.
    Secondary therapy:
    FC
    DOI:
    https://doi.org/10.1182/blood-2022-169928
    Trial ID:
    NCT04106076